94. Primary sclerosing cholangitis Clinical trials / Disease details


Clinical trials : 142 Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-001428-33-NL
(EUCTR)
27/07/202131/08/2020A study to assess efficacy, safety and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis)A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC) Primary sclerosing cholangitis (PSC)
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not yet established
Pliant Therapeutics, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Phase 2France;United States;Canada;Belgium;Austria;Australia;Norway;Germany;Netherlands;United Kingdom
2EUCTR2020-001428-33-DE
(EUCTR)
15/02/202117/07/2020A study to assess efficacy, safety and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis)A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC) Primary sclerosing cholangitis (PSC)
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not yet established
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not yet established
Pliant Therapeutics, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
112Phase 2France;United States;Canada;Belgium;Austria;Australia;Netherlands;Germany;United Kingdom
3EUCTR2020-001428-33-GB
(EUCTR)
05/11/202022/06/2020A study to assess efficacy, safety and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis)A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC) Primary sclerosing cholangitis (PSC)
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: PLN-74809
Product Code: PLN-74809
INN or Proposed INN: Not yet established
Pliant Therapeutics, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Phase 2United States;France;Canada;Belgium;Austria;Australia;Norway;Netherlands;Germany;United Kingdom
4NCT04480840
(ClinicalTrials.gov)
July 27, 202013/7/2020Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)Primary Sclerosing CholangitisDrug: PLN-74809;Drug: PlaceboPliant Therapeutics, Inc.NULLRecruiting18 Years75 YearsAll84Phase 2United States;Australia;Austria;Belgium;Canada;Germany;Netherlands;United Kingdom